enGene Therapeutics (ENGN) Shares Outstanding (2022 - 2026)
enGene Therapeutics (ENGN) posted quarterly Shares Outstanding (Entity) of $67.0 million for Q2 2026, up 31.17% year-over-year from $51.1 million in Q2 2025, and little changed quarter-over-quarter from $67.0 million in Q1 2026.
enGene Therapeutics (ENGN) Shares Outstanding (2022 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Shares Outstanding (Entity) for 5 consecutive years, with $67.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) rose 31.17% year-over-year to $67.0 million; the TTM figure through Apr 2026 stood at $67.0 million (up 31.17% YoY), while the FY2025 annual figure was $52.0 million, up 37.68% from the prior year.
- Shares Outstanding (Entity) held at $67.0 million in Q2 2026 per ENGN's latest filing, from $67.0 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $67.0 million in Q1 2026 and bottomed at $665767.0 in Q4 2022.
- Historically, Shares Outstanding (Entity) has averaged $32.8 million across 5 years, with a median of $44.2 million in 2024.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) rose 4.03% — and 2024, when it soared 6204.6%.
- enGene Therapeutics' Shares Outstanding (Entity) stood at $665767.0 in 2022, then gained by 4.03% to $692609.0 in 2023, then surged by 5355.08% to $37.8 million in 2024, then jumped by 37.68% to $52.0 million in 2025, then advanced by 28.78% to $67.0 million in 2026.
- Business Quant data shows ENGN's Shares Outstanding (Entity) at $67.0 million in Q2 2026, $67.0 million in Q1 2026, and $52.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | 69.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 69.72 Mn |
| Jan 31, 2026 | 67.26 Mn |
| Oct 31, 2025 | 51.12 Mn |
| Jul 31, 2025 | 51.10 Mn |
| Apr 30, 2025 | 51.02 Mn |
| Jan 31, 2025 | 50.98 Mn |
| Oct 31, 2024 | 37.78 Mn |
| Jul 31, 2024 | 44.17 Mn |
| Apr 30, 2024 | 39.44 Mn |
| Jan 31, 2024 | 23.20 Mn |
| Oct 31, 2023 | 692,609.00 |
| Jul 31, 2023 | 701,323.00 |
| Apr 30, 2023 | 694,497.00 |
| Jan 31, 2023 | 651,074.00 |
| Oct 31, 2022 | 655,153.00 |